NVS - NextCure's Big Rise And Fall And Other Headlines: The Good Bad And Ugly Of Biopharma

NextCure is down after trial data

NextCure (NXTC) is a recently IPO-ed small cap that has come under my radar mainly because of its tremendous rise after the IPO lock-up period. That is a very good sign; it basically shows the confidence insiders must have on the stock, since they did not flood the market with their option exercise shares after the mandatory 3-month period was over. Indeed, along with a healthy stake from Orbimed Advisors, there are only insider purchases, see below:

Source

However, the stock is now down again, over 50%,

Read more ...